A Novel Topical Ophthalmic Formulation to Mitigate Acute Mustard Gas Keratopathy In Vivo: A Pilot Study.
cornea
corneal edema
intraocular pressure
ocular inflammation
sulfur mustard
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
16
07
2020
accepted:
09
09
2020
entrez:
17
11
2020
pubmed:
18
11
2020
medline:
18
11
2020
Statut:
epublish
Résumé
This pilot study investigated the in vivo therapeutic potential and tolerability of a multimodal ophthalmic formulation, topical eye drops (TED), for acute mustard gas keratopathy (MGK) using a rabbit model. Twenty New Zealand White rabbits were used. Only right eyes of 18 rabbits (oculus dexter [OD]) received single sulfur mustard gas (SM) vapor injury, whereas contralateral eyes were left untreated or received TED for tolerabilty evaluation. Two rabbit eyes received no treatment and served as age-matched naive control. The four groups were: Naive (oculus sinister [OS] untreated eyes; n = 9); TED (OS treated only with TED BID for 3 days; n = 9); SM (OD exposed to SM vapor; n = 9); and SM+TED (OD exposed to SM+TED BID for 3 days; n = 9). Ocular examination in live rabbits were performed utilizing slit-lamp biomicroscopy, Fantes grading system, fluorescein staining, Schirmer's tests, pachymetry, and applanation tonometry. Cellular and molecular changes in rabbit corneas were assessed after humane euthanasia on day-3 and day-7 with histopathological and real-time polymerase chain reaction PCR techniques. TED to rabbit eyes was found tolerable in vivo. SM-exposed eyes showed significant increase in Fantes scores, central corneal thickness (CCT), Schirmer's test, epithelium-stroma separation, and corneal edema. TED mitigated clinical symptoms by reducing corneal edema, Fantes scores, CCT, and Schirmer's test. Further, TED decreased SM-induced corneal haze, inflammatory and profibrotic markers, transforming growth factor-TGF-β1 and cyclooxygenase-2COX-2, and damage to corneal structure, including epithelial-stromal integrity. The developed multimodal eyedrop formulation, TED, has potential to mitigate acute MGK effectively in vivo. TED is effective against MGK.
Identifiants
pubmed: 33200047
doi: 10.1167/tvst.9.12.6
pii: TVST-20-2844
pmc: PMC7645241
doi:
Substances chimiques
Mustard Gas
T8KEC9FH9P
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Pagination
6Subventions
Organisme : NEI NIH HHS
ID : R01 EY030774
Pays : United States
Organisme : BLRD VA
ID : IK6 BX005646
Pays : United States
Organisme : NEI NIH HHS
ID : U01 EY031650
Pays : United States
Organisme : BLRD VA
ID : I01 BX000357
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY017294
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY030234
Pays : United States
Informations de copyright
Copyright 2020 The Authors.
Déclaration de conflit d'intérêts
Disclosure: R. Tripathi, None; P.K. Balne, None; N.R. Sinha, None; L.M. Martin, None; S. Kamil, None; J.R. Landreneau, None; S. Gupta, None; J.T. Rodier, None; P.R. Sinha, None; N.P. Hesemann, None; A.C. Hofmann, None; M.K. Fink, None; S.S. Chaurasia, None; R.R. Mohan, None
Références
Stem Cells Transl Med. 2017 May;6(5):1356-1365
pubmed: 28276172
Acta Ophthalmol. 2010 May;88(3):337-41
pubmed: 19432862
Exp Eye Res. 2006 May;82(5):788-97
pubmed: 16303127
Immunopharmacol Immunotoxicol. 2018 Aug;40(4):290-296
pubmed: 29676192
Exp Eye Res. 2010 Sep;91(3):326-35
pubmed: 20599432
Arq Bras Oftalmol. 2015 Mar-Apr;78(2):67-72
pubmed: 25945524
Invest Ophthalmol Vis Sci. 1982 Mar;22(3):382-5
pubmed: 7061209
Curr Eye Res. 2001 Jan;22(1):42-53
pubmed: 11402378
J Refract Surg. 2004 Jan-Feb;20(1):76-8
pubmed: 14763475
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):1045-1057
pubmed: 29490341
J Appl Toxicol. 2004 Mar-Apr;24(2):107-13
pubmed: 15052605
Exp Eye Res. 2003 Mar;76(3):373-83
pubmed: 12573666
Toxicology. 2009 Sep 1;263(1):9-11
pubmed: 19486919
Invest Ophthalmol Vis Sci. 2005 May;46(5):1640-6
pubmed: 15851563
Cornea. 2012 Oct;31(10):1165-9
pubmed: 22832865
J Gerontol A Biol Sci Med Sci. 2019 Jul 12;74(8):1149-1157
pubmed: 30256910
J Refract Surg. 2012 Apr;28(4):285-90
pubmed: 22386369
Invest Ophthalmol Vis Sci. 2011 Jul 01;52(7):4833-41
pubmed: 21551414
Cell Stem Cell. 2010 Jan 8;6(1):71-9
pubmed: 20036631
Vet Ophthalmol. 2016 Nov;19(6):480-487
pubmed: 26559782
Trans Ophthalmol Soc U K. 1965;85:631-53
pubmed: 5227208
BMJ. 1991 Jan 19;302(6769):129-30
pubmed: 1822079
J Curr Glaucoma Pract. 2017 May-Aug;11(2):67-72
pubmed: 28924342
Proc R Soc Med. 1942 Jan;35(3):229-244.7
pubmed: 19992479
Plast Reconstr Surg. 2013 Sep;132(3):361e-71e
pubmed: 23985648
Cutan Ocul Toxicol. 2018 Dec;37(4):332-337
pubmed: 29648477
JAMA. 1980 Feb 15;243(7):623
pubmed: 7351790
Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3381-9
pubmed: 27367506
Cornea. 2012 Mar;31(3):280-90
pubmed: 22316652
Chest. 1999 May;115(5):1346-51
pubmed: 10334151
J Refract Surg. 2017 Dec 1;33(12):834-839
pubmed: 29227512
PLoS One. 2012;7(8):e42837
pubmed: 22900056
J Ocul Pharmacol Ther. 2010 Oct;26(5):407-19
pubmed: 20925577
Nat Commun. 2019 Apr 3;10(1):1496
pubmed: 30944320
Blood. 2007 Jan 1;109(1):31-9
pubmed: 16960145
Mol Vis. 2010 Apr 23;16:720-8
pubmed: 20431722
Toxicology. 2009 Sep 1;263(1):59-69
pubmed: 19061933
Mil Med. 2001 Jan;166(1):67-70
pubmed: 11197102
Clin Toxicol (Phila). 2016;54(2):79-91
pubmed: 26692048
Prehosp Disaster Med. 2009 Jan-Feb;24(1):19-29; discussion 30-1
pubmed: 19557954
Ann N Y Acad Sci. 2010 Apr;1194:72-80
pubmed: 20536452
Exp Eye Res. 2019 Oct;187:107705
pubmed: 31226339
Invest Ophthalmol. 1976 Dec;15(12):986-93
pubmed: 992963
Mol Vis. 2015 Aug 28;21:974-84
pubmed: 26330748
Acta Ophthalmol. 2013 Feb;91(1):e35-40
pubmed: 23035792
Ther Adv Chronic Dis. 2019 Jul 18;10:2040622319862697
pubmed: 31367296
Ophthalmology. 2005 Apr;112(4):617-25
pubmed: 15808253
Toxicol Appl Pharmacol. 2012 Oct 1;264(1):23-31
pubmed: 22841772
J Appl Toxicol. 2000 Dec;20 Suppl 1:S109-14
pubmed: 11428620
J Invest Dermatol. 1947 Aug;9(2):75-85
pubmed: 20266663
Basic Clin Pharmacol Toxicol. 2006 Oct;99(4):273-82
pubmed: 17040211
Am J Kidney Dis. 1999 Sep;34(3):445-55
pubmed: 10469854
Biophys J. 2003 Oct;85(4):2205-12
pubmed: 14507686
Int J Mol Med. 2008 Nov;22(5):651-5
pubmed: 18949386
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1681-3
pubmed: 10845585
Surv Ophthalmol. 1997 May-Jun;41(6):461-6
pubmed: 9220568
Ophthalmology. 1998 Sep;105(9):1775-9
pubmed: 9754191
Biomaterials. 2010 Feb;31(5):964-74
pubmed: 19853296